

Index

Note: Page numbers followed by *f* indicate a figure on the corresponding page. Page numbers followed by *t* indicate a table on the corresponding page.

- abnormal fetal growth, 271–3
- abnormal fetal heart rate, 252–3
- acardiac twin pregnancy. *see* twin-reversed arterial perfusion syndrome
- active delivery approach, 262
- activity and exercise during pregnancy
 - facts of, 286
 - issues with, 286
 - lifestyle considerations, 286–7
 - management options, 286
- adjustment to parenting, 306–7
- Advanced Dynamic Flow (ADF), 320
- air travel during pregnancy, 287
- American College of Obstetricians and Gynecologists (ACOG), 6–8, 72, 253–4, 259
- American Institute of Ultrasound in Medicine (AIUM), 72
- American Society for Reproductive Medicine (ASRM), 6, 7–8
- amniocentesis
 - DNA fingerprinting with, 55
 - invasive prenatal diagnosis with, 54, 74, 92, 93, 94–5, 320
 - process of, 95
 - timing of, 97
- amniocytosis. *see also* monochorionic diamniotic (MCDA) pregnancies
 - defined, 31
 - diagnosis of, 181, 182*f*
 - diamniotic twins, 32, 33–4*f*
 - dichorionic diamniotic twins, 32, 33–4*f*, 43–4, 202–3, 241
 - fetal growth restriction risks, 168–9
 - in higher-order multiple pregnancies, 35–6, 37*f*
 - introduction to, 18–20, 19*f*
 - monoamniotic twins, 32–4, 35*f*, 36*f*
 - overview of, 31–2
 - prenatal determination of, 32–4
 - pseudoamnioticity, 34
 - ultrasound findings, 181
- amniotic fluid (AF)
 - amniocentesis and, 95
 - bipolar coagulation and, 42
 - in cephalic twins, 262–3, 266
 - embolism, 347
 - evaluation of, 135, 184, 245–6, 262
 - fetoscopy and, 138
 - prenatal echocardiogram and, 102
 - preterm birth risk and, 206
 - reduction of, 159
 - sampling of, 235
 - TAPS and, 139, 148–9, 153
 - TTTS and, 137, 141, 142–3, 148–9, 182–3, 274
- anaemia, 39, 93, 128–31, 226, 236, 340, 341. *see also* twin anemia polycythemia syndrome
- analgesia use during vaginal delivery, 260
- aneuploidy screening, 114, 222, 223*t*, 237
- angiography imaging, 105
- anovulatory infertility, 11–13
- antenatal care
 - consultation for, 276–7
 - corticosteroids use, 227–8
 - in early pregnancy, 221–2
 - education classes, 297–8
 - existing guidelines, 221
 - fetal growth pathology, 224, 225*t*
 - how/when to deliver, 228–9, 230–1*t*
 - informational and emotional support, 228
 - introduction to, 221
 - maternal complications, 226–7
 - monochorionicity
 - complications, 225–6
 - nutritional supplements, diet, lifestyle, 228
 - planning and purpose of, 228
 - for preterm labour, 227
 - referral to tertiary fetal services, 229
 - screening for fetal complications, 222–6
 - screening for structural abnormalities, 223–4
- antenatal ultrasound, 70, 71
- antibiotic use, 43, 278
- apparent diffusion coefficient (ADC), 324
- appropriate-for-gestational age (AGA), 271–3
- arterio-arterial (A-A)
 - anastomosis, 78–9, 158–9, 320, 322
- arterio-venous (A-V)
 - anastomosis, 78–9, 320, 322
- artery-to-vein anastomoses, 273–5
- assisted conception
 - for anovulatory infertility, 11–13
 - facts on, 11
 - for IVF, 13–14
 - for unexplained infertility, 13
- assisted hatching, 202
- assisted reproductive technologies (ART)
 - avoidance of multiple pregnancy, 201–2
 - DZ twins from, 5
 - gestational dating and, 50, 52
 - higher-order pregnancies from, 233

- (ART) (cont.)
 methodology of, 7
 modifying risk factors, 6
 multiple pregnancies from,
 1, 2*f*, 3, 8, 233
 MZ twins from, 3–4
 placental pathophysiology
 and, 189
 assisted ventilation, 277
 Association for Improvements in
 the Maternity Services
 (AIMS), 293
 atypical twinning, 3
- bacterial vaginosis screening,
 207*t*, 207
 bed rest, 210, 286
 bereavement support, 304, 334
 bipolar cord occlusion (BCO),
 41–2, 118, 126, 177
 body mass index (BMI), 5,
 282–4, 285
 BOLD-MRI, 324
 Bracht manoeuvre, 265
 Braxton Hicks, John, 263–4
 breastfeeding
 challenges with multiples,
 198, 307–8
 overview, 278–9
 resources for parents, 336
 support for, 276
 breech-presenting twin, 253,
 263–6, 343
 British Fertility Society, 14
- cardiac examination of
 conjoined twins, 105–6
 cardiotocograph (CTG) short-
 term variation, 174–5
 cardiovascular disease,
 maternal, 197
 cardiovascular outcomes after
 fetoscopic laser
 surgery, 140
 cell-free DNA (cfDNA) testing,
 55–6, 60–3, 222
 Centers for Disease Control and
 Prevention (CDC), 6, 191
 cephalic/breech twins
 delivery, 263
 cephalic/cephalic twins
 delivery, 261–3
 cephalic/non-cephalic twins
 delivery, 263
 cephalic/oblique or
 transverse, 266
- cephalopagus twins, 99–100
 cerebral palsy (CP), 126, 221,
 275, 276
 cervical cerclage
 controversy over, 211
 history-indicated use, 211
 management options, 213
 meta-analysis/systemic
 review of, 212–13
 for multiples only, 211
 physical exam-indicated
 use, 212
 in preterm birth (PB)
 prevention, 211–13
 rescue cerclage, 212
 ultrasound-indicated use,
 212, 217
 cervical examination and
 preterm birth, 206
 cervical pessary
 definition and usage, 213–14
 management options, 214
 meta-analyses/systematic
 review, 214
 for preterm birth prevention,
 213–14
- caesarean delivery
 management of MOMO
 pregnancies, 246
 maternal morbidity and,
 39, 196
 neonatal mortality and, 251
 obstetric anaesthesia during,
 345–6
 planned caesarean delivery,
 196, 251–5, 349
 post-caesarean analgesia,
 347–8, 348*f*
 in singleton pregnancy,
 249–51
 trial of labour after
 a previous caesarean, 255
- child abuse, 7
 ‘Choosing Wisely’
 programme, 212
 chorioamnionitis, 18
 chorionic villus
 sampling (CVS)
 fetal aneuploidies diagnosis
 with, 54
 in higher-order
 pregnancies, 235
 invasive prenatal diagnosis
 with, 92, 93, 94, 320
 for nuchal translucency
 screening, 58–9
- timing of, 97
 zygosity determination, 55
- chorionicity
 assessment importance, 97
 defined, 21
 dichorionicity, 23, 24*f*,
 27*f*, 28–9
 early first trimester, 23–5,
 24*f*, 26*f*
 establishing, 78
 fetal abnormality risks and,
 64–5*f*, 67–8*f*
 fetal growth restriction risks,
 168–9
 in higher-order multiple
 pregnancies, 35–6, 37*f*
 in higher-order
 pregnancies, 234
 impact on preterm birth,
 202–3
 introduction to, 18–20, 19*f*
 late first trimester, 25, 27*f*
 MFP with separate
 chorionicities, 44–6
 monochorionic twin
 pregnancy, 23–5, 28–9*f*, 32
 overview of, 21–2
 PAPP-A in dichorionic
 pregnancies, 59–60, 61
 prenatal determination
 of, 22–3
 second and third trimesters,
 25, 30*f*, 31*f*
 stillbirth and, 241, 242*f*
- chromosomal abnormalities/
 defects, 54, 58–9, 94
 chronic inter-twin transfusion
 imbalance, 149
 clomiphene citrate (CC), 11, 12
 co-bedding twins, 303
 combined delivery, 252
 complete moles, 3
 computed tomography
 angiogram (CTA), 105
 computed tomography (CT),
 104–5
 congenital abnormalities/
 anomalies, 182, 270, 273
 conjoined twinning
 anatomic classification, 108*t*
 cephalopagus twins, 99–100
 craniopagus twins, 101
 dorsal unions, 101
 embryology of, 99
 emergency separation, 107
 facts of, 99

- intrapartum
 management, 103
 ischiopagus twins, 100
 lateral unions, 100
 management of, 101–7,
 108–11f
 omphalopagus twins, 100
 parapagus twins, 100
 postnatal imaging, 104–6
 prenatal imaging, 101–3
 pygopagus twins, 101
 rachipagus twins, 101
 surgical simulation role in,
 107–9
 survival rates, 99
 theories of, 273
 thoracopagus twins, 100
 ventral unions, 99–100
 continuity of care, 329–30
 continuous electronic
 monitoring, 256
 cord complications, 275
 cord entanglement, 103,
 119–20, 120f, 181
 cordocentesis, 55, 154
 corticosteroids use, 227–8
 cotyledonary flows, 322–4
 craniopagus twins, 101
 Credé's manoeuvre, 265–6
 crown-rump length (CRL),
 48–51, 50f, 52, 66–9,
 69f, 78
 cryopreservation, 14
 cytogenetic testing, 95–6

 Data Safety Monitoring
 Board, 212
 Dear Orla (UK), 291
 Dekker, Rebecca, 300
 delivery mode
 breech-presenting twin, 253
 combined delivery, 252
 facts of, 249–51
 higher-order multiple
 pregnancies, 255
 issues with, 251–5
 management
 recommendations, 255–6
 monochorionic diamniotic
 pregnancies, 254
 monochorionic
 monoamniotic
 pregnancies, 253–4
 non-cephalic second twin
 and, 251–2
 preterm birth and, 254–5
 time interval between, 252–3
 delivery room
 management, 277
 delivery timing
 dichorionic twin pregnancy,
 242–3, 244t, 245t, 246f
 facts of, 241–2
 higher-order multiple
 pregnancies, 245
 importance of dating, 241
 issues with, 242–5
 management options, 245–6
 monochorionic-
 monoamniotic twin
 pregnancies, 244–5, 247f
 monochorionic twin
 pregnancy, 242–3, 244t,
 245t, 246f
 neonatal mortality, rate
 versus risk, 241–2
 stillbirth, rate versus risk,
 241, 242f
 triplet pregnancy and, 245
 Delphi process, 84
 diastolic notching, 184
 dichorionic-diamniotic
 (DCDA) twin
 pregnancies, 32, 33–4f,
 43–4, 202–3, 241
 dichorionic-triamniotic
 (DCTA) pregnancies,
 201–2, 238
 dichorionic-triamniotic (DT)
 triplet pregnancies, 40f,
 43, 142–3, 202, 245
 dichorionic twin pregnancy
 delivery timing and, 242–3,
 244t, 245t, 246f
 detection of, 23, 24f,
 27f, 28–9
 discordant fetal anomaly,
 115–17, 116f
 Down syndrome risk, 222
 euploid dichorionic twins, 67
 fetal growth restriction and,
 168, 171, 172–5, 176t
 nuchal translucency
 measurement, 69
 diet factors in DZ twin births, 5
 dietary care, 228
 diffusion-weighted imaging
 (DWI), 102, 324
 discharge home and
 follow-up, 278
 discordant fetal anomaly
 defined, 112, 271–3
 in dichorionic twins, 115–17,
 116f
 exceptional circumstances
 with, 119–21
 introduction to, 112
 management of, 114–19
 in monochorionic twins,
 117, 119f
 prenatal detection of, 114
 prevalence of, 112, 113f
 selective termination
 and, 117
 dividing membrane
 measurements, 31
 dizygous (non-identical) twins
 defined, 1, 2f, 18, 19f, 20, 37
 diamnionicity, 32, 33–4f
 dichorionicity, 23, 24f, 27f
 establishment of, 20–1
 fetal abnormalities risk, 65
 fetal aneuploidy risks, 54, 58
 fetal causes of fetal loss/
 mortality, 124
 placentas of, 22–3
 rates of, 8
 risk factors for, 4–5
 DNA fingerprinting, 55
 Doppler ultrasound
 diastolic notching on, 184
 in fetal growth restriction,
 172, 174–5, 176–7
 in placental vasculature and
 function, 320–4, 321f, 323f
 dorsal unions in conjoined
 twinning, 101
 Down syndrome, 54, 222, 223t

 echocardiography, 81, 102, 105,
 107, 182, 197, 224
 echoplanar imaging (EPI), 102
 egg donation, 15
 elective birth, 155, 241, 243
 elective single embryo
 transfer, 14
 electrocardiographic (ECG)
 imaging, 104, 105
 emergency separation of
 conjoined twins, 107
 emotional and mental well-being
 antenatal considerations,
 289–98
 antenatal education classes,
 297–8
 bereavement support, 304
 consequences of physical
 challenges, 297

- emotional and mental (cont.)
 external strains and stressors, 304–5
 family-integrated care, 302–3
 impact of contested interventions, 295–7
 introduction to, 289
 mental health support, 301–2
 NICU and special care environment, 301–5
 parent-centred birth experience, 298–301
 patient vignettes, 292, 293, 294, 299, 308
 postpartum well-being, 306–11
 psychological impact of high-risk label, 292–3, 293, 294
 psychosocial factors of patient, 291–2
 recognition and empathy, 289–90
 referrals for support, 290–1
 twinship and individuality, 303–4
- emotional antenatal support, 228
- epidemiology of multiple pregnancy
 facts on, 1–6
 management options, 6–8
 modifying risk factors, 6
 multifetal pregnancy reduction, 7, 8*t*
 overall incidences, 1, 2*f*, 3
- epidural analgesia, 260, 343–5
- ESPRiT study cohort, 169
- estimated date of delivery (EDD), 88, 89
- estimated fetal weight (EFW), 81, 125
- euploid dichorionic twins, 67
- European IVF Monitoring (EIM) Consortium, 238
- ex utero intrapartum treatment (EXIT), 107
- exchange transfusion, 84, 148, 154, 156, 226, 274
- exogenous surfactant, 271, 277
- external cephalic version (ECV) delivery, 251, 263
- Family Crisis Support service, 335
- family history and DZ twins, 4
- family-integrated care, 302–3
- family well-being during pregnancy. *see* emotional and mental well-being
- feeding resources for parents, 336
- Fertility Clinic Success Rate and Certification Act (1992), 6
- fetal abnormality screening
 chorionicity and, 64–5*f*, 67–8*f*
 crown-rump length (CRL) measurement, 66–9, 69*f*
 facts of, 64–70
 issues with, 70–4
 labelling twins, 70*f*, 71*f*, 74
 management of pregnancy, 73–4
 nuchal translucency measurement, 69–70
 role of ultrasound in, 72–3
- fetal aneuploidy screening
 cell-free DNA testing, 55–6, 60–3
 facts of, 54
 by first-trimester combined test, 59–60, 62
 issues with, 54–6
 management options, 56*t*, 62
 by maternal age, 56–8, 59*t*, 62
 by nuchal translucency, 58–9
 in presence of a vanishing twin, 62, 63
 by second-trimester serum biomarkers, 60
- fetal blood sampling (FBS), 93
- fetal causes of fetal loss/mortality, 124
- fetal complications
 abnormal fetal heart rate, 252–3
 antenatal care screening, 222–6
 as cause of preterm birth, 203–4
 obstetric anaesthesia risk of, 341–2
- fetal echocardiogram screening, 81
- fetal fibronectin (fFN) screening, 44, 207
- fetal growth restriction (FGR)
 antenatal care for, 224, 225*t*
 aetiology of, 168–9
- fetoscopic laser surgery and, 177–8
- inter-twin biometry discordance, 169
- introduction to, 168, 271–3
- management dilemma, 169–70
- management options, 170–1*f*, 172, 173*f*, 175*t*
- prediction of, 178
- prevalence of, 168, 169–74*t*
- role of intrauterine fetal intervention, 177–8
- selective growth restriction, 168, 170, 171–2, 174*t*, 177–8, 179
- selective termination and, 177
- summary of, 178
- timing delivery of DC twins, 172–5, 176*t*
- timing delivery of MC twins, 175–7
- fetal hydrops, 342
- fetal loss/mortality. *see also*
 intrauterine fetal death;
 neonatal mortality; single
 intrauterine fetal death
- aetiology of, 124–7
- bereavement support, 304
- facts of, 123–4
- fetal causes of, 124
- first trimester, 123
- hemodynamic changes, 41–3
- in higher-order pregnancies, 237
- iatrogenic fetal loss, 126
- intrauterine donor death, 139
- maternal causes of, 124
- in monochorionic-monoamniotic twins, 183, 184*f*
- perinatal mortality, 271, 318
- placental/membrane causes of, 125–6
- second trimester, 123–4, 318–19
- single fetal demise, 86, 123
- single intrauterine death, 203–4
- stillbirth, 39, 128–9, 169–70, 221, 241, 242*f*
- strangulation due to cord entanglement, 103

- surviving twin with fetal demise, 275
 third trimester, 123–4
 with trisomies, 56–8
 with TTTS, 125, 128, 276, 318–19
 fetal mapping, 74, 94
 fetal monitoring, 83, 238, 260, 267, 344
 fetal pulmonary maturation, 184
 fetoscopic laser surgery for TTTS
 cardiovascular outcomes after, 140
 coagulation of the anastomoses cures TTTS, 153
 of connecting vessels, 177–8
 fetal complications, 139
 introduction to, 137–8
 maternal complications, 139
 neurodevelopmental impairment after, 140
 optimal technique for, 142
 outcomes after, 140
 overview, 137–40
 perinatal survival after, 140
 of placental anastomoses, 183
 TAPS occurrence after, 147, 149–51, 152f, 156
 technique of, 138
 timing and mode of delivery after, 143
 fetus *in fetu*, 3
 first trimester
 detrimental effect of elective cerclage, 211
 early first-trimester chorionicity, 23–5, 24f, 26f
 fetal aneuploidy screening, 59–60, 62
 interventions for TRAP, 162, 163, 166
 labelling twins in, 71, 74
 late first-trimester chorionicity, 25, 27f
 maternal complications in, 192
 prediction of twin-to-twin transfusion syndrome, 136
 screening for twin-to-twin transfusion syndrome, 80
 single fetal demise, 123
 ultrasound role in, 72
 fission theory, 273
 fluoroscopy of conjoined twins, 104
 follicle-stimulating hormone (FSH), 4–5, 11–12
 fragile X mental retardation 1 (FMR1) gene, 5
 free β -hCG risk assessment, 59–60, 61, 62
 frozen embryo replacements (FET), 11
 fusion theory, 99, 273
 gamete intrafallopian transfer (GIFT), 5
 general anaesthesia, 345
 genetic factors and DZ twins, 4–5
 genetic screening
 in low-risk pregnancy, 72
 multifetal pregnancy reduction and, 41, 44–5, 46
 nuchal translucency measurement and, 69
 preimplantation genetic screening, 5
 reviewing options for, 88
 zygosity and, 64
 gestational dating
 choosing fetus for, 48–50, 51f
 crown-rump length measurements, 48–51, 50f, 52
 importance of, 241
 introduction to, 48
 issues with, 48–50
 management of, 50–1, 51f
 when and how, 48, 50f
 gestational diabetes mellitus (GDM), 39, 193, 226, 236
 gonadotrophin-releasing hormone (GnRH), 4, 11
 Gratacos classification of sFGR, 179
 Green-Top guideline number 51 on the management of monochorionic pregnancy, 329
 growth differentiation factor 9 (GDF9) gene, 4
 Growth Restriction Intervention Trial (GRIT), 174
 hearing deficit, 278
 haemorrhage
 intraventricular haemorrhage, 185, 254, 275, 278
 as maternal complications, 39, 197, 236, 341
 obstetric anaesthesia and, 346–7
 postpartum haemorrhage, 88, 103, 196–7, 255, 341, 348, 349
 heterokaryotypic twins, 20, 28, 96, 117
 heterotopic pregnancies, 3
 Higgins Nutritional Intervention Program, 284
 High-intensity focused ultrasound (HIFU), 325–6
 higher-order multiple (HOM) pregnancies. *see also* triplet pregnancy
 assisted reproductive technologies and, 201–2
 defined, 35
 delivery mode, 255
 delivery timing, 245
 determination of chorionicity and amnionicity, 35–6, 37f
 discordant fetal anomaly, 121
 facts on, 233, 234t
 invasive prenatal diagnosis, 96
 issues with, 234–6
 management options, 237
 medical complications, 236
 miscarriage risks, 235
 prenatal care of, 234–5
 prenatal diagnosis of, 235
 prenatal imaging/screening, 235
 preterm birth prevention, 217
 risk factors, 6, 23
 risks with, 235–6
 spontaneous preterm birth, 227, 236
 vaginal delivery of, 267–8
 Home-Start website, 335
 home uterine activity monitor (HUAM), 206–7
 Human Fertilisation and Embryology Authority (HFEA), 6, 7, 14

- hyperbilirubinemia, 274, 278
hyperemesis gravidarum, 39, 236
hypertension/hypertensive disorders, 39, 226, 236, 341
hypogonadotrophic hypogonadism
 anovulatory infertility, 11–13
iatrogenic fetal loss, 126
ICOMBO (International Council of Multiple Birth Organisations), 290
identical twins. *see* monozygous (identical) twins
immunization
 administration, 278
in utero magnetic resonance imaging (iuMRI), 129
in vitro fertilization (IVF)
 avoidance of multiple pregnancy, 201–2
 data and statistics on, 6
 dizygous (non-identical) twins from, 1
 multiple pregnancy rates with, 11, 13–14, 201–2
 ovarian induction for, 13–14
 preterm birth and, 205
informational antenatal support, 228
Institute of Medicine (IOM), 192
inter-twin biometry
 discordance, 169
inter-twin delivery interval, 252–3, 256
internal podalic version and breech delivery, 263–6, 264–5*f*
International Society of Ultrasound in Obstetrics & Gynecology (ISUOG), 72, 246
interstitial laser technique, 118, 120–1, 131, 165–6*f*
intracytoplasmic sperm injection (ICSI), 202, 205
intrafetal laser coagulation, 163, 166
intrapartum management
 in conjoined twinning, 103
intrauterine donor death, 139
intrauterine fetal death. *see also* fetal loss/mortality; single intrauterine fetal death
 fetal anomaly and, 117
 monochorionic monoamniotic twins and, 244–5
 overview of, 183, 184*f*
 rates in smaller twin, 82
 rates with multiples, 233
 selective demise, 43
 TTTS and, 137, 139, 342
intrauterine growth restriction (IUGR), 22, 44, 45–6, 125, 271–3. *see also* selective intrauterine growth restriction
intrauterine insemination (IUI), 8, 11–13
intrauterine transfusion (IUT), 129, 154
intraventricular haemorrhage, 185, 254, 275, 278
invasive prenatal diagnosis
 amniocentesis, 92, 93, 94–5, 320
 chorionic villus sampling, 92, 93, 94, 320
 delayed cytogenetic testing, 95–6
 facts of, 92–3
 fetal blood sampling, 93
 introduction to, 92
 issues with, 94–6
 management of procedures, 96–7
 pregnancy loss with, 95, 97
 special considerations, 95–6
 technical considerations, 94–5
ischiopagus twins, 100
ISUOG Practice Guidelines on the role of ultrasound in twin pregnancy, 329
JUmeaux MODE d'Accouchement (JUMODA) study, 251
labelling twins, 70*f*, 71*f*, 74, 78
lambda sign, 29, 30*f*, 64
language barriers to care, 291
laparoscopic ovarian diathermy, 12
large-for-gestational age (LGA), 271–3
laser coagulation in umbilical cord occlusion, 41–2
lateral unions in conjoined twinning, 100
Levet, André, 266
lifestyle care/considerations
 activity and exercise during pregnancy, 286–7
 introduction to, 282
 nutrition and weight gain during pregnancy, 282–6
 nutritional supplements, 228
 travel during pregnancy, 287–8
long-term outcomes, 43, 275–6
Lovset's manoeuvre, 265
low birthweight
 after egg donation, 15
 cervical cerclage and, 211–12
 delivery mode and, 254–5, 256
 description of, 271–3
 in dichorionic twin pregnancies, 11, 205
 hospitalization risks, 276
 in multiples, 249, 307
 reduced risks of, 238, 284
Luke, Barbara, 284
Lullaby Trust, 337
luteinizing hormone (LH), 4, 11–12
magnetic resonance
 cholangiopan creatography (MRCP), 105
magnetic resonance imaging (MRI), 102, 104, 105, 129, 320, 325
maternal age
 chromosomal abnormality risks, 114
 delivery modes and, 250
 DZ twins and, 4, 8, 65
 fetal aneuploidy screening by, 54, 55, 56–8, 59*t*, 62, 92, 235
 morbidity risks and, 341
 NT screening and, 58–60, 63, 222
 optimizing delivery outcomes, 197
 preterm births and, 11
 screening by serum markers, 60
 triplets and higher-order multiples, 6, 92, 233

- maternal body composition, 5
- maternal complications
 addressing risks of, 191
 anaemia, 39, 93, 128–31, 226, 236, 340, 341
 antenatal care for, 226–7
 cardiovascular disease, maternal, 197
 causes of fetal loss, 124
 depression, 7
 facts on, 188–91
 in first trimester, 192
 gestational diabetes mellitus, 39, 193, 226, 236
 haemorrhage concerns, 39, 197, 236, 341
 hypertension/hypertensive disorders, 39, 226, 236
 issues of, 191–3
 management options, 193–9
 maternal morbidity, 188, 189*f*
 mirror syndrome, 106, 120, 342
 mitigating risk at delivery, 196–8, 197*t*
 neonatal outcomes versus, 193, 195*f*, 199
 patient-level
 pathophysiology, 188–90, 190*t*
 placenta and, 189
 population-level data on, 190–1
 postpartum maternal care, 198*f*, 199
 pre-eclampsia, 195, 204–5, 341
 smoking during pregnancy, 204
 in third trimester, 192–3, 194*t*
 vaginal birth safety, 196, 199
 venous thromboembolism, 193
- maternal fetal medicine specialist, 72, 73
- maternal morbidity
 maternal age and, 341
 multifetal pregnancy reduction and, 39, 46
 with multiple pregnancies, 221
 obstetric anaesthesia risk, 341
 overview of complications, 188, 189*f*
- maternal serum genetic screening, 69–70
- Mauriceau, Francois, 266
- maximum fecundity, 6
- medical complications of HOM pregnancies, 236
- mental health support, 301–2, 337
- mental well-being. *see* emotional and mental well-being
- Michigan Multiples Clinic, 284
- middle cerebral artery peak systolic velocity (MCA-PSV), 84, 85*f*, 128, 129, 147, 148*f*, 149, 151, 155
- mirror syndrome, 106, 120, 342
- miscarriage rates/risks
 after sIUFD, 132–3
 amniocentesis and, 93, 95
 bipolar cord occlusion and, 118
 cytogenetic testing and, 96
 embryo versus fetal reduction, 40–1, 44
 fetal reduction and, 237–8
 invasive prenatal diagnosis and, 95, 97
 invasive tests and, 54, 58
 of monochorionic pregnancies, 125–6, 320
 progesterone administration and, 216
 second entry trocar, 164
 selective termination and, 58, 116, 117, 202
 single twin fetal loss and, 123
 TAPS and, 125
 triplets and higher-order multiples, 235
 TTTS and, 243
- monochorionic-diamniotic (MCDA) pregnancies
 defined, 78, 158
 delivery mode and, 254
 preterm birth risk and, 202–3
 stillbirth and, 241
 twin-to-twin transfusion syndrome and, 203
- monochorionic-monoamniotic (MCMA) twin pregnancies. *see also* twin to twin transfusion syndrome
 complications, 182–3, 275
- congenital
 abnormalities, 182
 defined, 78, 158, 181
 delivery mode, 253–4
 delivery timing of, 244–5, 247*f*
 diagnosis of, 101, 181, 182*f*
 discordant fetal anomaly, 119–20, 120*f*
 facts on, 181–3
 fetal abnormalities risk, 64
 fetal loss and, 125–6, 127
 frequency and setting of surveillance, 184–5
 intrauterine fetal death, 183, 184*f*
 introduction to, 32–4, 35*f*, 36*f*, 38
 issues with, 183–4
 management options, 184–5
 methods of surveillance, 184
 MFPR not recommended for, 43
 mode of delivery, 185
 rate of congenital anomalies, 88
 screening and diagnosis of, 86–8, 87*f*
 selective growth restriction with, 78, 183
 timing of birth, 185
 TTTS in, 136
 twin-to-twin transfusion syndrome in, 182–3
- monochorionic twin pregnancy
 after in vitro fertilization, 202
 complications with, 78, 225–6
 delivery timing and, 242–3, 244*t*, 245*t*, 246*f*
 discordant fetal anomaly, 117, 119*f*
 Down syndrome risk, 222
 facts of, 77*t*, 78
 fetal aneuploidy risks, 58, 60, 62
 fetal growth restriction and, 168, 171–2, 175–7
 invasive prenatal diagnosis, 96
 issues with, 78–88
 management of, 88–9
 multifetal pregnancy reduction and, 41–3

- monochorionic twin (cont.)
 nuchal translucency
 measurement, 69–70
 overview of, 23–5, 28–9f,
 32, 37
 perinatal mortality, 271, 318
 placental disease
 understanding, 319
 preterm birth risk
 assessment, 88
 screening and diagnosis
 techniques, 86–8
 selective termination
 in, 45–6
 single intrauterine death,
 203–4
 structural anomalies, 88
 vascular anastomoses, 78–9,
 318–19
 MONOMONO study, 88
 monosomy X screening, 56–8
 monozygous (identical) twins.
 see also conjoined
 twinning
 after in vitro
 fertilization, 202
 defined, 1–3, 18, 19f, 20,
 37, 158
 discordant fetal anomaly
 risk, 112
 fetal abnormalities risk, 65–6
 fetal aneuploidy risks, 55, 58
 fetal causes of fetal loss/
 mortality, 124
 monoamniotic twins, 32–4,
 35f, 36f
 monochorionic twin
 pregnancy, 23–5, 28–9f, 32
 placenta of, 22
 rates of, 8
 risk factors for, 3–4, 14
 TTTS in, 158
 multifetal pregnancy reduction
 (MFPR)
 facts of, 39–41, 40f
 genetic screening and, 41, 46
 in higher-order multiple
 pregnancies, 237–8
 introduction to, 7, 8t, 15
 loss rates, 39
 management of pregnancies
 after, 44
 post-reduction pregnancy
 management, 45, 46
 pre-pregnancy counselling
 and, 44–5
 preterm birth risk and, 202
 protocol for, 45
 with separate
 chorionicities, 44–6
 timing of, 40–1
 in twin and triplet
 pregnancies, 43–4
 multinomial logistic regression
 analysis, 205
 National Academy of
 Medicine, 282
 National Institute for Health
 and Care Excellence
 (NICE) (UK)
 care pathway and parents’
 proforma
 endorsement, 331
 cephalic presentation of
 presenting fetus, 259
 on caesarean delivery, 253–4
 drop in multiple live birth
 rates and, 14
 Guideline 137 for Twin and
 Triplet Pregnancy, 329
 Hypertension in Pregnancy
 guidelines, 226
 multiple pregnancy
 guidelines, 221, 229
 preterm labour
 predictions, 227
 Quality Standard 46 for
 Twin and Triplet
 Pregnancy, 329, 330f, 331
 neonatal care
 abnormal fetal growth,
 271–3
 adverse outcomes, 270–1
 antenatal consultation,
 276–7
 breastfeeding, 198, 276,
 278–9
 congenital abnormalities/
 anomalies, 182, 270, 273
 cord complications, 275
 delivery room
 management, 277
 discharge home and follow-
 up, 278
 issues with, 270
 long-term outcomes, 275–6
 management of multiple
 pregnancy deliveries,
 276–9
 neonatal intensive care unit,
 252, 270, 277–8, 279
 non-presenting
 newborns, 275
 parental support, 279
 perinatal depression, 275
 perinatal morbidity, 270
 perinatal mortality, 271
 placental vascular
 anastomoses and, 273–5
 prematurity, 271, 272f
 resources for parents, 334
 respiratory distress, 275
 surviving twin with fetal
 demise, 275
 neonatal intensive care unit
 (NICU), 252, 270,
 277–8, 279
 bereavement support, 304
 emotional and mental well-
 being of, 301–5
 external strains and
 stressors, 304–5
 family-integrated care,
 302–3
 mental health support in,
 301–2
 support frameworks and self
 confidence, 309–10
 twinship and individuality,
 303–4
 neonatal mortality. *see also*
 fetal loss/mortality
 antenatal care and, 229
 in breech-presenting
 twins, 253
 cervical cerclage and, 211
 caesarean delivery and,
 251
 iatrogenic preterm delivery
 risk and, 125, 132
 with multifetal
 gestations, 210
 NICE guidelines on, 221
 preterm delivery and,
 216, 243
 rates of risk, 241–2, 267
 risk with multiples, 39
 selective growth restriction
 and, 125
 stillbirth risks, 241
 TAPS and, 148
 twin TOLAC and, 255
 neurodevelopmental
 impairment, 140, 171,
 275–6, 319
 neurological morbidity in
 fetus, 41–3

- NICHD Human Placenta Project, 319
- non-cephalic second twin delivery, 251–2
- non-invasive intrauterine treatments, 325–6
- non-invasive prenatal diagnosis (NIPD), 325
- non-invasive prenatal testing (NIPT), 222, 325
- non-presenting newborns, 275
- non-vertex-presenting twin, 266–7
- North American Fetal Therapy Network (NafNET), 72
- nuchal translucency measurement, 58–9, 69–70, 114
- nutrition and weight gain during pregnancy
body mass index, 282–4, 285
facts of, 282–4*t*
issues with, 285
lifestyle considerations, 282–6
management options, 285–6
- nutritional supplements, 228
- obesity epidemic, 5
- obstetric anaesthesia
for caesarean delivery, 345–6
during delivery, 342–6
- epidural analgesia, 343–5
- fetal complications risk, 341–2
- general anaesthesia, 345
- haemorrhage and, 341, 346–7
- introduction to, 340
- maternal morbidity risk, 341
- maternal physiological changes and, 340
- planned vaginal delivery and, 343–5, 344*f*
- post-caesarean analgesia, 347–8, 348*f*
- pre-eclampsia and, 341
- twin-to-twin transfusion syndrome and, 342
- omphalopagus twins, 100
- ovarian hyper-stimulation syndrome (OHSS), 5, 7, 14, 202
- ovarian induction (OI)
for anovulatory infertility, 11–13
for IVF, 13–14
risk of multifetal gestation, 8
for unexplained infertility, 13
- ovarian reserve, 4
- overt systolic failure, 197
- oxygen therapy, 277
- oxytocin use, 256
- PAPP-A in dichorionic pregnancies, 59–60, 61
- parapagus twins, 100
- Paré, Ambroise, 263–4
- Paré technique, 264–5
- parent-centred birth experience
changing language around birth, 300
emotional and mental well-being of, 298–301
environment of, 300–1
mode of birth, 298
support for, 300
- parent resources
on bereavement, 334
on feeding, 336
on mental health, 337
for multiple pregnancies, 333–7, 338*f*
on neonatal care, 334
on practical challenges, 335, 336*f*
on pregnancy, 333
on sleep, 336
summary and further support, 337
- parental support, 279
- parents of multiples (PoMs), 289, 290, 297–8
- parity increase and DZ twins, 4
- passive delivery approach, 262
- patent ductus arteriosus, 278
- patient-level pathophysiology, 188–90, 190*t*
- peer support, 297
- perinatal depression, 275
- perinatal morbidity, 46, 64, 168, 201, 210, 217, 233, 270, 275, 341
- perinatal mortality
antenatal care and, 318
cerclage in twin gestation, 212
caesarean delivery and, 253
of conjoined twins, 99, 110
of MCMA twins, 87
- modes of conception and, 205
- in MOMO twin pregnancies, 244
- of monoamniotic twins, 183
- in monochorionic twins, 168
- overview of, 271
- TTTS and, 137, 141
- UK-MBRRACE reports, 123
- perinatal switch, 71
- periventricular leukomalacia, 275
- physical exam-indicated cervical cerclage (PEIC), 212
- Pinard manoeuvre, 265
- placental angiogenesis, 135
- placental disease
understanding, 319
- placental/membrane causes of fetal loss, 125–6
- placental vascular anastomoses, 273–5
- placental vasculature and function assessment, 320–4, 321*f*, 323*f*
- planned caesarean delivery, 196, 251–5, 349
- planned vaginal delivery (VD), 250–1, 252, 253, 343–5, 344*f*
- polycystic ovary syndrome (PCOS) anovulatory infertility, 11–13
- post caesarean analgesia, 347–8, 348*f*
- postnatal imaging in conjoined twinning, 104–6
- postnatal support resources, 333*f*, 332
- postpartum depression, 39, 185, 236, 306–7, 337
- postpartum haemorrhage, 88, 103, 196–7, 255, 341, 348, 349
- postpartum maternal care, 198*f*, 199
- postpartum well-being
breastfeeding multiples, 307–8
life with multiples, 310–11
overview of, 306–11
recovery and adjustment to parenting, 306–7
support frameworks and self confidence, 309–10

- practical challenges resources
for parents, 335, 336f
- Practical Preparing for
Parenthood course, 335
- Prague manoeuvre, 266
- pre-pregnancy counselling,
44–5, 46, 106
- pre-eclampsia, 195, 204–5, 341
- pregnancy loss. *see* miscarriage
rates/risks
- pregnancy management with
multiples
facts of, 318
issues with, 318–20
placental vasculature and
function assessment,
320–4, 321f, 323f
research avenues, 320–6
- pregnancy resources for
parents, 333
- preimplantation genetic
screening (PGS), 5
- premature cervical shortening
in TTTS, 141
- prematurity, 271, 272f
- prenatal care of higher-order
multiple pregnancies,
234–5
- prenatal determination/
diagnosis, 22–3, 32–4, 235.
see also invasive prenatal
diagnosis
- preterm birth (PTB), 39
after multifetal pregnancy
reduction, 44
amniotic fluid and, 206
avoidance of multiple
pregnancies, 201–2
bacterial vaginosis screening
and, 207t, 207
cervical examination
and, 206
chorionicity impact on,
202–3
of conjoined twins, 103
contraception mode impact
on, 205
delivery mode, 254–5
fetal complications as cause,
203–4
fetal fibronectin and, 207
home uterine activity
monitor and, 206–7
introduction, 201
maternal indications for,
204–5
- multifetal pregnancy
reduction and, 202
pathophysiology, 201
pre-eclampsia and, 204–5
prematurity, 271, 272f
preterm labour care, 227
prevention of multiple
pregnancies, 201–2
previous history of, 204
race/ethnicity impact on, 205
risk assessment, 88
risks of, 221
single intrauterine death,
203–4
smoking during
pregnancy, 204
spontaneous preterm birth,
227, 236
transvaginal ultrasound
cervical length and, 205–6
twin-to-twin transfusion
syndrome and, 203
- preterm birth (PTB)
prevention
cervical cerclage, 211–13
cervical pessary, 213–14
hospitalization and bed
rest, 210
introduction to, 210
management of, 218t
progesterone
supplementation, 214–17
in triplets and higher-order
pregnancies, 217
- preterm delivery (PTD), 270–1,
272f
- preterm premature rupture of
the membranes (PPROM),
103, 126, 139, 203, 270
- progesterone supplementation
management options,
216–17
meta-analyses of, 216
in preterm birth prevention,
214–17
- 17-alpha-
hydroxyprogesterone
caproate (17-OHPC),
215–16, 217
twins with short cervix,
215–16
unselected twins and, 215
vaginal-micronized
progesterone, 215,
216, 217
- prophylactic tocolytes, 210
- pseudoamnionicity, 34
- psychological impact of high-
risk label, 292–3, 293,
294
- psychosocial factors of patient,
291–2
- pygopus twins, 101
- Quadratus lumborum block
(QLB), 347–8
- quantitative fluorescent
polymerase chain reaction
(QF-PCR) analysis, 93, 96
- Quintero staging criteria, 136,
137t
- race/ethnicity factors, 4, 205
- rachipagus twins, 101
- radiofrequency ablation (RFA)
in fetal growth restriction,
171–2, 177
iatrogenic cause of fetal
loss, 126
intrauterine fetal therapy,
171–2
selective termination with,
118, 318
TRAP and, 164, 165–6f, 210
in umbilical cord occlusion,
41–2, 118, 119f, 131,
177
- radiograph use in conjoined
twinning, 104
- randomised controlled trials
(RCTs), 12, 13, 142, 213,
215, 229, 249, 253, 347
- receiver operating characteristic
(ROC) curve, 205
- recovery and adjustment to
parenting, 306–7
- rescue cerclage, 212
- resources for multiple
pregnancies
care in practice guidelines,
329–30, 331f
outcome guidelines and
policies, 329, 330f
for parents, 333–7, 338f
for postnatal support,
333f, 332
support for health
professionals, 330–3
Twins Trust's Maternity
Engagement Quality
Improvement project, 329,
331, 332f

- respiratory distress, 151,
211–12, 215, 216, 233,
244–5, 270, 274, 275
- retinopathy of prematurity, 278
- routine hospitalization, 210
- Royal College of Obstetricians
and Gynaecologists
(RCOG), 175
- SANDS (UK), 291
- seasonal variation in DZ twin
births, 5
- second trimester
fetal aneuploidy
screening, 60
fetal loss, 123–4
interventions for TRAP, 164
screening for twin-to-twin
transfusion syndrome, 80
ultrasound role in, 72
- selective fetoscopic laser
photocoagulation
(SFLP), 342
- selective growth restriction
(sFGR)
antenatal care, 224, 225*t*
fetal growth restriction and,
168, 170, 171–2, 174*t*,
177–8, 179
higher-order multiple
pregnancies, 236
in monoamniotic twins,
78, 183
- selective growth restriction
(sGR), 125
- selective intrauterine growth
restriction (sIUGR), 64,
78, 81–4, 82*f*, 82*t*, 83*f*,
147, 203
- selective termination (ST)
defined, 39
discordant fetal anomaly
and, 117
fetal abnormality and, 73
fetal growth restriction
and, 177
management of pregnancies
after, 44
miscarriage rates/risks, 58,
116, 117, 202
in monochorionic twin
pregnancy, 45–6
protocol for, 45
psychological impact of, 294
with radiofrequency
ablation, 318
- radiofrequency ablation and,
118, 318
- reducing preterm birth
risk, 202
- in separate
chorionicities, 44–6
timing of MFPR, 40–1
twin anaemia polycythemia
syndrome and, 154–5
- 17-alpha-hydroxyprogesterone
caproate (17-OHPC),
215–16, 217
- sex determination of fetus, 28
- sexual activity during
pregnancy, 286
- single fetal demise, 86, 123
- single intrauterine fetal death
(sIUFD)
avoidance of, 127–8
avoiding co-twin sequelae
following, 129–31
co-twin survivors of, 126
delivery after, 132
issues with, 127–33
monitoring after, 128–9,
130*f*, 131*f*
pregnancy-associated risks,
126, 127*t*
pregnancy management
after, 132–3
in twin and preterm birth,
203–4
- single-nucleotide
polymorphisms, 21
- single-shot fast spin echo
(SSFSE), 102
- Sleep Expectations
factsheet, 337
- sleep resources for parents, 336
- Sleep Top Tips for Multiples
factsheet, 337
- small-for-gestational age
(SGA), 271–3
- Smellie, William, 266
- smoking during
pregnancy, 204
- Society for Reproductive
Technology (SART), 6
- Society of Maternal Fetal
Medicine (SMFM), 259
- Society of Obstetricians and
Gynaecologists of Canada
(SOGC), 253–4
- spontaneous preterm birth
(SPTB), 227, 236. *see also*
preterm birth
- stillbirth, 128–9, 169–70, 221,
241, 242*f*
- STOPPIT2 trial, 214
- strangulation due to cord
entanglement, 103
- sudden infant death syndrome
(SIDS), 337
- superb microvascular imaging
(SMI), 320
- superfetation, defined, 3
- superovulation, 7, 11,
13–14, 233
- surviving twin with fetal
demise, 275
- suture ligation in umbilical
cord occlusion, 41–2
- swallowing anomalies, 117
- T-sign, 64
- T₁-weight gradient echo
(GRE), 102
- T₂-weighted single-shot
fast spin echo
(SSFSE), 102
- TBS study, 249–50
- Term Breech Trial, 253
- termination of pregnancy in
conjoined twinning, 106
- thermal-neutral
environments, 277
- third trimester, 123–4, 192–3,
194*t*
- thoracopagus twins, 100
- thromboelastometry, 347
- thrombosis risks, 287
- tocolytic agents, 210
- tomographic ultrasound
imaging (TUI), 320
- total vascular resistance
(TVR), 190
- transvaginal ultrasound, 12,
66, 73
- transvaginal ultrasound
cervical length (TVUCL),
205–6
- transversus abdominis plane
block (TAP), 347–8
- travel during pregnancy
facts of, 287
issues with, 287
lifestyle considerations,
287–8
management options,
287–8
- trial of labour after a previous
caesarean (TOLAC), 255

- trichorionic triamniotic (TCTA) pregnancies, 43–4, 202
- triplet pregnancy. *see also* higher-order multiple (HOM) pregnancies
 delivery timing and, 245
 dichorionic-triamniotic triplets, 40f, 43, 142–3, 202, 245
 dichorionicity, 23
 multifetal pregnancy reduction in, 43–4
 preterm birth prevention, 217
 twin-to-twin transfusion syndrome in, 142–3
 vaginal delivery of, 267–8
- trisomy 13 screening, 54, 55, 56–8, 115, 222–3
- trisomy 18 screening, 54, 55, 56–8, 115, 222–3
- trisomy 21 screening, 56–8, 59, 62, 114, 115, 222–3
- TRUFFLE trial (Trial of Umbilical and Fetal Flow in Europe), 174
- twin anaemia polycythemia syndrome (TAPS)
 after fetoscopic laser surgery, 139
 after fetoscopic laser surgery for TTTS, 147, 149–51, 152f, 156
 amniotic fluid and, 139, 148–9, 153
 characterization of, 148–9, 155
 as chronic inter-twin transfusion imbalance, 149
 clinical outcomes, 273–4
 defined, 125, 147, 151
 detection with MCA-PSV, 147, 148f, 149, 151, 155
 elective birth and, 155
 expectant management of, 152
 facts of, 147–9, 148t, 150–1f
 fetoscopic laser coagulation of anastomoses for, 153
 in higher-order multiple pregnancies, 236
 intrauterine transfusion of donor with exchange transfusion, 154
 issues with, 78, 149–51, 152f
 management options, 152–5, 153–4f
 miscarriage rates/risks, 125
 neonatal mortality, 148
 occurrence after fetoscopic laser surgery, 147, 149–51, 152f, 156
 overview, 84, 85f, 85t, 225–6
 preterm birth and, 203
 selective termination and, 154–5
- Twin Birth Study (TBS), 249, 343, 346
- twin pregnancies. *see also* conjoined twinning;
 specific twin pregnancies
 after egg donation, 15
 atypical twinning, 3
 birth rates, 1
 heterokaryotypic twins, 20
 incidence of, 1–3, 2f
 inter-twin biometry discordance, 169
 labelling twins, 70f, 71f, 78
 multifetal pregnancy reduction in, 43–4
 omphalopagus twins, 100
 parapagus twins, 100
 rachipagus twins, 101
 surviving twin with fetal demise, 275
 thoracopagus twins, 100
 vanishing twin pregnancy, 3, 62, 63, 237
- twin-reversed arterial perfusion syndrome (TRAP)
 acardiac twin pregnancy in, 157–8
 complications with, 78
 defined, 157, 166, 182, 274–5
 early intervention, 162, 163
 expectant management, 162–3
 facts of, 157–9, 160–1t
 first-trimester diagnosis, 162, 163, 166
 incidence of, 157
 intrafetal laser coagulation, 163, 166
 issues in, 159–62
 late intervention, 164, 166–7
 management options, 43, 162–4, 165–6f
 overview of, 84–6, 86f, 120–1
- radiofrequency ablation and, 164, 165–6f, 210
- second-trimester interventions, 164
- ultrasound monitoring and, 159
- twin-to-twin transfusion syndrome (TTTS). *see also* fetoscopic laser surgery for TTTS
 amniotic fluid and, 137, 141, 142–3, 148–9, 182–3, 274
 anastomoses with, 79f, 79
 clinical outcomes, 273–4
 complications with, 64–6, 78
 diagnosis of, 81, 135–6
 Doppler ultrasound changes characteristic of, 183
 fetal demise with, 276
 fetal growth differences, 169
 fetal loss/mortality, 125, 128, 276, 318–19
 fetal loss with, 125, 128, 276, 318–19
 fetoscopic laser surgery, 137–40, 153
 first-trimester screening for, 80
 incidence in MCMA twins, 87, 182–3
 intrauterine fetal death, 137, 139, 342
 introduction to, 79, 80t, 135
 management of Stage I TTTS, 141
 miscarriage rates/risks, 243
 in monochorionic-monoamniotic twins, 87, 182–3
 monozygous (identical) twins, 158
 nuchal translucency thickness and, 69–70
 obstetric anaesthesia management of, 342
 overview of, 79–81, 225
 perinatal mortality, 137, 141
 placental vasculature and function assessment, 321–4, 323f
 prediction in first trimester, 136

- premature cervical shortening, 141
 preterm birth and, 203
 screening with fetal echocardiogram, 81
 second-trimester screening for, 80
 summary of, 143
 TAPS after fetoscopic laser surgery for, 147, 149–51, 152*f*, 156
 treatment of, 137–8
 in triplets, 142–3
 ultrasound staging systems, 136, 137*t*
 vascular anastomoses, 78, 79*f*
 Twins Trust's BeCOME survey, 329, 333*f*, 332
 Twins Trust's CPD website, 332
 Twins Trust's Maternity Engagement Quality Improvement project, 329, 331, 332*f*
- UK-MBRRACE perinatal mortality reports, 123–4
 ultrasound monitoring. *see also* Doppler ultrasound
 after single intrauterine fetal death, 128
 in amnionity diagnosis, 181
 of conjoined twins, 102, 103, 104
 delivery mode and, 255
 dividing membrane measurements, 31
 fetal growth restriction and, 170, 172
 gestational dating, 48
 high-intensity focused ultrasound, 325–6
 in higher-order pregnancies, 234
 iatrogenic fetal loss, 126
 for intrauterine growth restriction, 45–6
 introduction to, 12
 mapping of fetuses, 45
 of monochorionic pregnancies, 89
 role in fetal abnormality screening, 72–3
 as screening for structural abnormalities, 223
 staging systems for twin-to-twin transfusion syndrome, 136, 137*t*
 tomographic ultrasound imaging, 320
 twin-reversed arterial perfusion syndrome and, 159
 use in cerclage, 212, 217
 umbilical artery Doppler velocimetry, 128
 umbilical cord occlusion, 41–2, 118–19
 uterine incision, 268
- vaginal delivery (VD)
 active approach, 262
 analgesia use, 260
 birth safety, 196, 199
 cephalic/breech twins, 263
 cephalic/cephalic twins, 261–3
 cephalic/non-cephalic twins, 263
 cephalic/oblique or transverse, 266
 external cephalic version, 251, 263
 facts of, 259–68
 fetal monitoring, 260
 of higher-order multiples, 267–8
 internal podalic version and breech delivery, 263–6, 264–5*f*
 issues with, 268
 labour during, 260
 labour patterns in twins, 260
 methodology of, 261–7
 non-vertex-presenting, 266–7
 passive approach, 262
 planning of, 261
 preparation for, 259–60
 of triplets, 267–8
 of twins, 259–67
 uterine incision, 268
 vaginal-micronized progesterone, 215, 216, 217
 vanishing twin pregnancy, 3, 62, 63, 237
 vascular anastomoses, 78–9, 164
 vascular disruption sequence, 274–5
 Veit, Gustave, 266
 Veit, Mauriceau Smellie, 265–6
 veno-venous (V-V) anastomosis, 78–9, 158–9
 venous thromboembolism (VTE), 193
 ventral unions in conjoined twinning, 99–100
 virtual fetoscopy technique, 322
 voiding cystoureterogram (VCUG), 104
 vulnerable child syndrome, 309
- well-being during pregnancy. *see* emotional and mental well-being
 work restrictions during pregnancy, 286
 World Health Organization, 191
- zygosity
 chorionic villus sampling and, 55
 defined, 20
 dizygosity, 20–1
 genetic screening and, 64
 introduction to, 18–20, 19*f*
 overview, 20, 21*f*
 testing for, 290
 zygote intrafallopian transfer (ZIFT), 5